The clinical failures of poziotinib, and other irreversible EGFR inhibitors72–74, on patients previously treated with EGFR inhibitors may be a result of dose limiting toxicities which are difficult to readout in preclinical cancer models. This evidence concerns the gene EGFR and cancer.